The Clinical Usefulness of Nuclear Matrix Protein-22 in Patients with Atypical Urine Cytology

다국어 초록 (Multilingual Abstract)

Purpose: Difficulty exists in interpreting the significance of atypical urine cytology. This study was performed to assess the diagnostic utility of nuclear matrix protein-22 (NMP-22) testing when atypical cells are detected during urine cytology.
Materials and Methods: Among patients whose urine cytology was reported as atypical between January 2004 and December 2009, a total of 275 who also underwent NMP-22 testing were enrolled in the present study. These patients were further divided into the screening group (143 patients examined as outpatients for hematuria) and the follow-up group (132 patients followed up for previously diagnosed bladder cancer). The sensitivity, specificity, positive and negative predictive values, and accuracy were assessed for atypical cytology alone and in conjunction with NMP-22.
Results: Of the 275 patients exhibiting atypical urine cytology, cancer was confirmed in 85, yielding a positive predictive value of 30.9% (85/275). Of the 96 patients testing positive for NMP-22, 58 were diagnosed with bladder cancer. The positive predictive value in conjunction with NMP-22 was 60.4% (58/96). The sensitivity, specificity, negative predictive value, and accuracy were 68.2% (58/85), 80.0% (152/190), 84.9% (152/179), and 76.2% (210/275), respectively. Testing for NMP-22 in the screening and follow-up groups increased the positive predictive value from 30.0% (43/143) to 64.0% (32/50) and from 31.3% (42/132) to 56.5% (26/46), respectively; there was no significant difference between the screening and follow-up groups (p=0.106).
Conclusions: When only cases with atypical urine cytology were examined, NMP-22 testing increased the detection rate of bladder cancer regardless of whether the test was used in screening hematuria or in following up patients.

다국어 초록 (Multilingual Abstract)

Purpose: Difficulty exists in interpreting the significance of atypical urine cytology. This study was performed to assess the diagnostic utility of nuclear matrix protein-22 (NMP-22) testing when atypical cells are detected during urine cytology.
Materials and Methods: Among patients whose urine cytology was reported as atypical between January 2004 and December 2009, a total of 275 who also underwent NMP-22 testing were enrolled in the present study. These patients were further divided into the screening group (143 patients examined as outpatients for hematuria) and the follow-up group (132 patients followed up for previously diagnosed bladder cancer). The sensitivity, specificity, positive and negative predictive values, and accuracy were assessed for atypical cytology alone and in conjunction with NMP-22.
Results: Of the 275 patients exhibiting atypical urine cytology, cancer was confirmed in 85, yielding a positive predictive value of 30.9% (85/275). Of the 96 patients testing positive for NMP-22, 58 were diagnosed with bladder cancer. The positive predictive value in conjunction with NMP-22 was 60.4% (58/96). The sensitivity, specificity, negative predictive value, and accuracy were 68.2% (58/85), 80.0% (152/190), 84.9% (152/179), and 76.2% (210/275), respectively. Testing for NMP-22 in the screening and follow-up groups increased the positive predictive value from 30.0% (43/143) to 64.0% (32/50) and from 31.3% (42/132) to 56.5% (26/46), respectively; there was no significant difference between the screening and follow-up groups (p=0.106).
Conclusions: When only cases with atypical urine cytology were examined, NMP-22 testing increased the detection rate of bladder cancer regardless of whether the test was used in screening hematuria or in following up patients.

참고문헌 (Reference)

1 Feifer AH, "Utility of urine cytology in the workup of asymptomatic microscopic hematuria in low-risk patients" 75 : 1278-1282, 2010

2 최화섭, "Usefulness of the NMP22BladderChek Test for Screening and Follow-up of Bladder Cancer" 대한비뇨기과학회 51 (51): 88-93, 2010

3 Brown FM, "Urine cytology. It is still the gold standard for screening" 27 : 25-37, 2000

4 Jo MK, "The significance of atypical cell in urinary cytology" 39 : 9-14, 1998

5 Raina R, "The clinical utility of atypical cytology is significantly increased in both screening and monitoring for bladder cancer when indexed with nuclear matrix protein-22" 102 : 297-300, 2008

6 Ponsky LE, "Screening and monitoring for bladder cancer: refining the use of NMP22" 166 : 75-78, 2001

7 Farrow GM, "Pathologist’s role in bladder cancer" 6 : 198-206, 1979

8 Farrow GM, "Pathologist’s role in bladder cancer" 6 : 198-206, 1979

9 Gupta NP, "Nuclear matrix protein 22 as adjunct to urine cytology and cystoscopy in follow-up of superficial TCC of urinary bladder" 73 : 592-596, 2009

10 Karakiewicz PI, "Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder" 97 : 997-1001, 2006

11 Nabi G, "How important is urinary cytology in the diagnosis of urological malignancies" 43 : 632-636, 2003

12 Sharma S, "Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat" 162 : 53-57, 1999

13 Melamed MR, "Developments in cytological diagnosis of cancer" 50 : 651-666, 1966

14 Melamed MR, "Developments in cytological diagnosis of cancer" 50 : 651-666, 1966

15 Kapila K, "Could nuclear matrix 22(NMP22) play a role with urine cytology in screening for bladder cancer? – experience at Kuwait University" 19 : 369-374, 2008

16 Miyanaga N, "Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer" 31 : 163-168, 1997

17 Deshpande V, "Analysis of atypical urine cytology in a tertiary care center" 105 : 468-475, 2005

18 Khadra MH, "A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice" 163 : 524-527, 2000